HIV and Antiretrovirals Impact Diverse Gut Microbiomes

In a groundbreaking, multicohort study published in 2025, researchers have unveiled intricate details of how the human immunodeficiency virus (HIV) and its treatments distinctly sculpt the gut microbiome across diverse geographic populations. This extensive investigation encompassed 587 individuals, comprising both HIV-positive patients and HIV-uninfected controls, from Uganda, Botswana, and the United States. Using advanced fecal metagenomic sequencing, the study sheds light on how HIV infection, disease progression, and antiretroviral regimens differentially affect the taxonomic landscape and functional capacity of resident gut microbial communities, underscoring the nuanced interplay between host immunity, treatment, and geography in microbiome dynamics.

Traditionally, the gut microbiome has been recognized as a pivotal modulator of host health and immune responses. HIV infection, characterized by immunodeficiency and chronic inflammation, has been known to perturb gut microbiota composition and function. However, previous investigations were limited by geographic homogeneity and inconsistencies in antiretroviral treatment regimens, leading to ambiguous conclusions about the microbiome changes attributable to HIV versus therapy effects. By expanding the scope to include cohorts from sub-Saharan Africa and North America, the present study offers a comprehensive panorama of microbiome alterations linked to HIV, antiretroviral drugs, and their intersection influenced by environmental and population-specific factors.

One of the major findings is that taxonomic modifications in the gut microbiota induced by HIV infection are largely site-specific. Diversity metrics and bacterial taxa shifts differed substantially between Ugandan and Botswanan cohorts compared to the USA cohort, signifying that geography and local ecology substantially mold microbial responses to HIV. This geographic variance in bacterial community structure likely reflects differences in diet, lifestyle, and baseline microbiota composition that converge with the impact of immunodeficiency, resulting in distinct microbial ecosystems. Such results emphasize the necessity of incorporating diverse populations when evaluating microbiome changes in disease contexts, rather than generalizing findings from single-region studies.

Despite marked regional differences in bacterial species composition, alterations in microbial functional pathways were found to be remarkably consistent across the three examined cohorts. Functional metagenomic analyses revealed convergent perturbations in metabolic processes including amino acid metabolism, lipid biosynthesis, and redox balance, which intensified in individuals exhibiting acquired immunodeficiency syndrome (AIDS). This suggests that although the identity of the microbial players varies geographically, the biochemical repercussions of HIV-induced dysbiosis share commonalities, potentially contributing to systemic inflammation and immune dysfunction observed in HIV progression.

A striking aspect revealed relates to how antiretroviral therapy (ART), cornerstone in HIV management, imprints on the gut microbiome in a geography-dependent manner. The study highlights that the commonly used non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz, produced divergent microbial effects in the African cohorts compared to the USA cohort. In Uganda and Botswana, efavirenz administration correlated with depletion of Prevotella species—commensal bacteria often implicated in mucosal immune modulation—and disruption of bacterial interspecies metabolic networks. Conversely, such changes were less pronounced or absent in the USA cohort, once again underscoring the modulating influence of environmental and host factors beyond HIV viral status or ART receipt alone.

The depletion of Prevotella prompted deeper mechanistic investigations given its links to health outcomes. Computational modeling and in vitro experiments illuminated a novel hypothesis wherein efavirenz cross-inhibits prokaryotic reverse transcriptases involved in bacterial antiphage defense mechanisms. These reverse transcriptases are integral to bacterial adaptive immunity against bacteriophages, and their inhibition could impair microbial survival and community balance. This unexpected off-target effect of efavirenz provides a molecular foothold explaining Prevotella reduction and poses critical questions about how ART-associated microbial perturbations might exacerbate immune activation and comorbidities such as atherosclerosis, which were observed concomitantly in the African cohorts.

Chronic systemic inflammation in people living with HIV is a key driver of non-AIDS-defining illnesses, including cardiovascular diseases. By linking efavirenz-associated Prevotella depletion to heightened inflammation and atherosclerosis markers, this study intricately connects ART-induced gut microbiome changes to downstream clinical sequelae. Such findings underscore the imperative to consider microbiome consequences in ART selection, particularly in resource-limited settings where certain regimens prevail. Tailoring therapy with microbiome preservation in mind could mitigate long-term adverse events and improve quality of life for millions.

Furthermore, this research exemplifies the complexity of host-microbiome-therapy interactions. It challenges the simplistic notion of ART effects as universally beneficial or solely focused on viral suppression, illuminating a layered landscape where treatment exerts distinct biological forces on commensal ecosystems conditioned by geography and host background. This multidimensionality advocates for precision medicine approaches that integrate microbiome profiling and geographic context into clinical decision-making.

The comprehensive metagenomic approach adopted here enabled dissection of taxonomic shifts alongside functional gene repertoires, painting a holistic picture of microbiome dynamics rather than one limited to microbial census. This is critical because functional redundancy among microbial taxa often conceals deeper ecosystem impacts; hence, identifying convergent pathway disruptions amidst taxonomic heterogeneity is particularly insightful. The study also reveals opportunities for therapeutic innovation targeting modifiable microbial pathways or mitigating ART off-target effects.

Looking ahead, these findings open several promising avenues for research and application. Longitudinal studies could elucidate causal relationships between therapy-induced microbiome changes and clinical outcomes over time. Additionally, development of adjunctive microbiome-modulating interventions, such as prebiotics or targeted bacteriophage therapies, might optimize HIV care. Moreover, integrating microbiome assessments into global HIV treatment programs could harmonize infection control with microbiome stewardship, enhancing holistic patient health.

This work also exemplifies the power of international collaborative research, integrating cohorts from diverse continents to uncover universal and local microbial effects of HIV and its treatment. Such model studies are essential to bridge global health disparities and tailor medical interventions that respect biological and cultural heterogeneity. Ultimately, acknowledging and interrogating the interface of infectious disease, microbiome ecology, geography, and pharmacology offers transformative potential for advancing personalized and global health.

In summary, this landmark study decisively broadens our understanding of how HIV and antiretroviral therapy reshape the gut microbiome across populations with distinct environmental and genetic backgrounds. It challenges prior assumptions by revealing geography-specific taxonomic modifications but functional commonalities, as well as identifying deleterious microbiome effects linked to a widely used ART agent. These insights not only deepen our mechanistic grasp of microbial-host-virus-drug interplay but also herald a new frontier wherein microbiome-informed, geography-tailored HIV treatment strategies could significantly attenuate complications and elevate patient outcomes worldwide. The implications for clinical practice and public health policy are profound and serve as a clarion call for integrating microbiome science into the future of HIV medicine.